Arsenic Trioxide Liposomes: Encapsulation Efficiency and In Vitro Stability

References

• Zhang P, Wang S Y, Hu X H. Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. Chin J Hematol 1996; 17: 58–62
   Google Scholar
• Shen Z‐X, Chen Q, Ni J H, Li X S, Xiong S M, Qiu Q Y, Zhu J, Tang W, Sun G L, Yang K Q, Chen Y, Zhou L, Fang Z W, Wang Y T, Ma J, Zhang P, Zhang T D, Chen S J, Chen Z, Wang Z Y. Use of arsenic trioxide in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354–3360, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Soignet S L, Maslak P, Wang Z G, Jhanwar S, Calleja E, Dardashti L J, Carso D, De Blasio A, Gabrilove J, Scheinberg D A, Pandolfi P P, Warrell R P, Jr. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339: 1341–1348, [PUBMED], [INFOTRIEVE], [CROSSREF], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Akao Y, Nakagawa Y, Akiyama K. Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Lett 1999; 455: 59–62, [PUBMED], [INFOTRIEVE], [CROSSREF], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Chen G Q, Shi X G, Tang W, Xiong S‐M, Zhu J, Cai X, Han Z‐G, Ni J H, Shi G Y, Jia P M, He K L, Niu C, Ma J, Zhang P, Zhang T D, Paul P, Naoe T, Kitamura K, Miller W, Waxman S, Wang Z Y, de The H, Chen S J, Chen Z. Use of arsenic trioxide in the treatment of acute promyelocytic leukemia (APL): I. As203 exerts dose‐dependent dual effects on APL cells. Blood 1997; 89: 3345–3353, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Shao W, Fanelli M, Ferrara F F, Riccioni R, Rosenauer A, Davison K, Lamph W W, Waxman S, Pelicci P G, Le Coco F, Avvisati G, Testa U, Peschle C, Gambacorti‐Passerini C, Nervi C, Miller W H, Jr. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 1998; 90: 124–133, [PUBMED], [INFOTRIEVE], [CROSSREF], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lu M, Levin J, Sulpice E, Sequeira‐Le Grand A, Alemany M, Caen J P, Han Z C. Effect of arsenic trioxide on viability, proliferation, and apoptosis in human megakaryocytic leukemia cell lines. Exp Hematol 1999; 27: 845–852, [PUBMED], [INFOTRIEVE], [CROSSREF], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Huff J, Waalkes M, Nyska A, Chan P. Re: apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst 1999; 91: 1690–1691, [PUBMED], [INFOTRIEVE], [CROSSREF], [CROSSREF]
   Google Scholar
• Westervelt P, Pollock J, Haug J, Ley T J, DiPersio J F. Response and toxicity associated with dose escalation of arsenic trioxide in the treatment of resistant acute promyelocytic leukemia. Blood 1997; 90(suppl 1)249b
   Google Scholar
• Roboz G J, Diaz S, Lam G, Lane W L, Soignet S L, Warell R P, Rafii S. Arsenic trioxide induces dose‐ and time‐dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 2000; 96: 1525–1530, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Gregoriadis G. Liposome Technology2nd ed. CRC Press, Boca Raton, FL 1993
   Google Scholar
• Lasic D D, Papahadjopoulos D. Medical Applications of Liposomes. Elsevier Science B.V., Amsterdam 1998
   Google Scholar
• New R RC. Liposomes: A Practical Approach, R RC New. IRL Press Oxford University Press, Oxford 1990; 134–255
   Google Scholar
• Fatouros D, Antimisiaris S G. Physicochemical properties of liposomes incorporating hydrochlorothiazide and chlorothiazide. J Drug Targeting 2001; 9: 61–74
   PubMed Web of Science ®Google Scholar
• Kirby C, Gregoriadis G. Dehydration–rehydration vesicles: a simple method for high yield drug entrapment in liposomes. Biotechnology 1984; 2: 979–984, [CROSSREF], [CROSSREF]
   Web of Science ®Google Scholar
• Stewart J CM. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem 1980; 104: 10–14, [PUBMED], [INFOTRIEVE], [CROSSREF], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kokona M, Kallinteri P, Fatouros D, Antimisiaris S G. Stability of SUV liposomes in the presence of cholate salts and pancreatic lipases: effect of lipid composition. Eur J Pharm Sci 2000; 9: 245–252, [CROSSREF], [CROSSREF]
   Google Scholar
• Fatouros D, Hatzidimitriou K, Antimisiaris S G. Liposomes encapsulating prednisolone and prednisolone–cyclodextrin complexes: comparison of membrane integrity and drug release. Eur J Pharm Sci 2001; 13: 287–296, [PUBMED], [INFOTRIEVE], [CROSSREF], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Fatouros D, Antimisiaris S G. Effect of lipophilic drugs on the properties of their liposome formulations: a study with prednisolone, diazepam and griseofulvin. J Coll Interface Sci 2002; 251: 271–277, [CROSSREF], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Senior J, Gregoriadis G. Stability of small unilamellar liposomes in serum and clearance from the circulation: the effect of the phospholipid and cholesterol components. Life Sci 1982; 30: 2123–2136, [PUBMED], [INFOTRIEVE], [CROSSREF], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gortzi O, Papadimitriou E, Kontoyannis C G, Antimisiaris S G, Ioannou P V. Arsonoliposomes, a novel class of arsenic containing liposomes: effect of palmitoyl–arsonolipid containing liposomes on the viability of various cancer and normal cells in culture. Pharm Res 2002; 19(1)79–86, [PUBMED], [INFOTRIEVE], [CROSSREF], [CROSSREF]
   Google Scholar
• Gortzi O, Antimisiaris S G, Klepetsanis P, Papadimitriou E, Ioannou P V. Cytotoxicity of arsonolipid containing liposomes towards cancer and normal cells in culture: effect of arsonolipid acyl chain length. Eur J Pharm Sci 2003; 18(2)175–183, [PUBMED], [INFOTRIEVE], [CROSSREF], [CROSSREF]
   Google Scholar